95
Participants
Start Date
January 18, 2022
Primary Completion Date
March 22, 2025
Study Completion Date
March 25, 2025
XTX202
XTX202 Monotherapy
UPMC Hillman Cancer Center Pavilion, Pittsburgh
Georgetown University Medical Center, Washington D.C.
Carolina BioOncology Institute, Huntersville
Moffitt Cancer Center, Tampa
Sarah Cannon Research Institute, Nashville
The Ohio State University Wexner Medical Center James Cancer Hospital and Solove Research Institute, Columbus
University of Iowa Hospitals and Clinics, Iowa City
HealthPartners Cancer Center at Regions Hospital, Saint Paul
Norris Comprehensive Cancer Center, Los Angeles
University of California Los Angeles, Los Angeles
UC San Diego Moores Cancer Center, La Jolla
Hoag Memorial Hospital Presbyterian- Newport Beach, Newport Beach
Massachusetts General Hospital, Boston
Atlantic Health System/Morristown Medical Center, Morristown
Rutgers Cancer Institute of NJ, New Brunswick
Xilio Development, Inc.
INDUSTRY